Utah Retirement Systems’s Acadia Pharmaceuticals ACAD Stock Holding History

Utah Retirement Systems’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,700	Closed	-$305K	–	953
2020 Q4	$305K	Buy	+5,700	New	+$283K	﹤0.01%	856
2020 Q3	–	Sell	-4,600	Closed	-$223K	–	930
2020 Q2	$223K	Buy	+4,600	New	+$221K	﹤0.01%	933
2018 Q2	–	Sell	-18,300	Closed	-$411K	–	996
2018 Q1	$411K	Buy	18,300 +100	+0.5%	+$2.77K	0.01%	916
2017 Q4	$548K	Buy	18,200 +500	+3%	+$16K	0.01%	888
2017 Q3	$667K	Buy	17,700 +100	+0.6%	+$3.25K	0.02%	837
2017 Q2	$491K	Buy	17,600 +200	+1%	+$5.96K	0.01%	908
2017 Q1	$599K	Hold	17,400	–	–	0.01%	838
2016 Q4	$502K	Hold	17,400	–	–	0.01%	868
2016 Q3	$554K	Buy	17,400 +1,000	+6%	+$33.9K	0.01%	846
2016 Q2	$532K	Buy	+16,400	New	+$549K	0.01%	846

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Utah Retirement Systems's ACAD Position: Q1 2021 in Review

Utah Retirement Systems sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 5,700 shares — an estimated $305K sold.

Utah Retirement Systems first reported a position in ACAD in Q2 2016 and held it in 10 quarters. The position peaked at $667K in Q3 2017. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

Utah Retirement Systems reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Utah Retirement Systems sold 5,700 Acadia Pharmaceuticals shares in Q1 2021, an estimated $305K.
Utah Retirement Systems first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 10 quarters.
Utah Retirement Systems's Acadia Pharmaceuticals position peaked at $667K in Q3 2017.
272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Utah Retirement Systems's 13F filing for Q1 2021, filed 17 May 2021.